Dinar

Indication :

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefdinir and other antibacterial drugs, Cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial

therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

DINAR (cefdinir) capsules and DINAR (cefdinir) for oral suspension are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms

Composition :

DINAR Capsules contain 300 mg cefdinir and the following inactive ingredients: Docusate Sodium, Partially Pregelatinised Starch (Starch 1500), Povidone (PVP K30), Magnesium Stearate, Talc powder, Croscarmellose sodium, Isopropyl alcohol**, Purified Water**, Gelatin, Titanium dioxide, Brilliant blue, Erythrosine.

DINAR for Oral Suspension, after reconstitution, contains 250 mg cefdinir per 5 mL and the following inactive ingredients: Microcrystalline Cellulose and Carboxymethylcellulose Sodium (Neo-C91) , Sucrose, Sodium Benzoate, Mannitol, Carboxymethylcellulose sodium 1300 CPS, Colloidal silicon dioxide (Aerosil 200), Strawberry, Aspartame, Docusate sodium, Trisodium citrate dehydrate, Anhydrous Citric acid, Isopropyl alcohol *.

DINAR for Oral Suspension, after reconstitution, contains 125 mg cefdinir per 5 mL and the following inactive ingredients: Sucrose , Sodium Citrate , Citric acid ,Areosil 200 ,Strawberry flavor , Sodium Benzoate, Xanthan gum, Guar gum.